ChiCTR2100046816 版本V1.4 版本创建时间2022/01/10 14:33:54 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100046816 

最近更新日期:

Date of Last Refreshed on:

2021-12-24 16:28:39 

注册时间:

Date of Registration:

2021-05-28 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

PI3K/AKT信号通路对小于胎龄儿脑损伤中GABAA受体表达、调控及预后研究

Public title:

Effect of PI3K/AKT signaling pathway on GABA A receptor expression, regulation and prognosis in small for gestational age infants with brain injury

注册题目简写:

English Acronym:

研究课题的正式科学名称:

磁共振成像辅助下PI3K/AKT信号通路对小于胎龄儿脑损伤中GABAA受体表达、调控及预后研究

Scientific title:

Effect of PI3K/AKT signaling pathway on GABA A receptor expression, regulation and prognosis in small for gestational age infants with brain injury using MRI

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

祁英 

研究负责人:

祁英 

Applicant:

Qi Ying 

Study leader:

Qi Ying 

申请注册联系人电话:

Applicant telephone:

+86 18940258254

研究负责人电话:

Study leader's telephone:

+86 18940258254

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

womanman1982@163.com

研究负责人电子邮件:

Study leader's E-mail:

womanman1982@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

辽宁省沈阳市和平区三好街36号

研究负责人通讯地址:

辽宁省沈阳市和平区三好街36号

Applicant address:

36 Sanhao Street, Heping District, Shenyang, Liaoning

Study leader's address:

36 Sanhao Street, Heping District, Shenyang, Liaoning

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

中国医科大学附属盛京医院

Applicant's institution:

Shengjing Hospital of China Medical University

研究负责人所在单位:

中国医科大学附属盛京医院

Affiliation of the Leader:

Shengjing Hospital of China Medical University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2021PS094K

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中国医科大学附属盛京医院伦理委员会

Name of the ethic committee:

Ethics Committee of Shengjing Hospital Affiliated to China Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2021-02-24 00:00:00

伦理委员会联系人:

王洪

Contact Name of the ethic committee:

Wang Hong

伦理委员会联系地址:

辽宁省沈阳市和平区三好街36号

Contact Address of the ethic committee:

36 Sanhao Street, Heping District, Shenyang, Liaoning

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 18940252528

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

祁英

Primary sponsor:

Qi Ying

研究实施负责(组长)单位地址:

辽宁省沈阳市和平区三好街36号

Primary sponsor's address:

36 Sanhao Street, Heping District, Shenyang, Liaoning

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

辽宁

市(区县):

沈阳

Country:

China

Province:

Liaoning

City:

Shenyang

单位(医院):

中国医科大学附属盛京医院

具体地址:

和平区三好街36号

Institution
hospital:

Shengjing Hospital of China Medical University

Address:

36 Sanhao Street, Heping District

经费或物资来源:

沈阳市科技计划项目(项目编号:19-112-4-013)

Source(s) of funding:

Science and Technology Planning Project of Shenyang (grant numbers 19-112-4-013)

Target disease:

neonatal brain injury

Target disease code:

研究类型:

诊断试验

Study type:

Diagnostic test

研究所处阶段:

诊断试验新技术临床试验 

Study phase:

Diagnostic New Technique Clincal Study

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

应用磁共振检查观察SGA 新生儿脑微观结构、脑灌注、脑氧代谢率的变化,依据脑损伤类型、病灶大小、数量、形态、分布随访,为深入了解SGA脑损伤病理生理情况、病灶演变、预测患儿预后提供新思路。  

Objectives of Study:

To observe the changes of brain microstructure, cerebral perfusion and cerebral oxygen metabolism rate in neonates with SGA by magnetic resonance imaging. According to the type of brain injury, the size, number, shape and distribution of lesions, follow-up was conducted to provide reference for further understanding the pathophysiology of brain injury, the evolution of lesions and predicting the prognosis of children with SGA.

药物成份或治疗方案详述:

选取来我院新生儿病房新生儿为研究对象,在获得监护人知情同意书及伦理委员会同意权的前提下,观察SGA 新生儿磁共振检查脑微观结构、脑灌注、脑氧代谢率的变化,探讨SGA 脑损伤病理生理变化、病灶演变、患儿预后。 

Description for medicine or protocol of treatment in detail:

The changes of brain microstructure, cerebral perfusion and cerebral oxygen metabolism rate of SGA newborns were observed under the premise of informed consent of guardians and consent of ethics committee. The pathophysiological changes, lesion evolution and prognosis of SGA brain injury were discussed. 

纳入标准:

1.中国医科大学附属盛京医院新生儿;
2.出生后1-2天的健康和SGA新生儿(SGA新生儿是指新生儿出生体重低于同胎龄同性别平均出生体重的两个标准差);
3.获得监护人知情同意书及伦理委员会同意权。

Inclusion criteria

1. Neonates from Shengjing Hospital of China Medical University;
2. Healthy and SGA newborns 1-2 days after birth (SGA newborns are defined as newborn birth weight is less than two standard deviations of the mean birth weight for the same gestational age and sex.);
3. Obtain informed consent from the guardian and consent from the Ethics Committee.

排除标准:

1. 颅内感染、遗传代谢性脑病、先天畸形者。

Exclusion criteria:

1. Intracranial infection, hereditary metabolic encephalopathy and congenital malformation.

研究实施时间:

Study execute time:

From 2022-01-01 00:00:00 To 2024-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-01-01 00:00:00 To 2024-11-30 00:00:00  

诊断试验:

Diagnostic Tests:

金标准或参考标准(即可准确诊断某疾病的单项方法或多项联合方法,在本研究中用于诊断是否有该病的临床参考标准):

临床资料、实验室检查、磁共振成像结果。

Gold Standard or Reference Standard (The clinical reference standards required to establish the presence or absence of the target condition in the tested population in present study):

Clinical data, laboratory examination and MRI results.

指标试验(即本研究的待评估诊断试验,无论为方法、生物标志物或设备,均请列出名称):

全脑血流量、脑氧代谢率、静脉氧饱和度。

Index test:

Cerebral blood flow, cerebral metabolic rate of oxygen, oxygen saturation fractions in venous blood.

目标人群(可以是某种疾病患者或正常人群,详细描述其疾病特征,注意应纳入符合分布特点的全序列病例,具有良好的代表性)

小于胎龄新生儿100例、健康对照新生儿20例。

例数:

Sample size:

120

Target condition (The target condition is a particular disease or disease stage that the index test will be intended to identify. Please specify the characteristics in detail; the population should has a complete spectrum and good representative):

There were 100 newborns for gestational age and 20 healthy controls.

容易混淆的疾病人群(即与目标疾病不易区分的一种或多种不同疾病,应避免采用正常人群对照的病例-对照设计):

低体重儿、早产儿。

例数:

Sample size:

0

Population with condition difficult to distinguish from the target condition, the normal population in a case-control study design should be avoid:

Low birth weight infant, preterm infant.

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

辽宁 

市(区县):

沈阳 

Country:

China 

Province:

Liaoning 

City:

Shenyang 

单位(医院):

中国医科大学附属盛京医院 

单位级别:

三级甲等 

Institution
hospital:

Shengjing Hospital of China Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

体重

指标类型:

次要指标

Outcome:

birth weight

Type:

Secondary indicator

测量时间点:

出生

测量方法:

体重秤测量

Measure time point of outcome:

at birth

Measure method:

Scale measurement

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 0 years
最大 Max age 2 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机数表法,独立研究者

Randomization Procedure (please state who generates the random number sequence and by what method):

random number tables, independent researcher

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

论文见刊后即可公布

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

open access to the data after our manuscript of the study has been pulished in the journal

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

纸质版CRF表进行信息获取,双人同时将数据录入至Epidata

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

We will fill out the case report form (CRF) for each patient, then two investigators will input one CRF into Epidata simultaneously.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-05-28 22:22:43